Stock Research Monitor: ARDX, BOLD, and AUPH
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on ARRY sign up now at www.wallstequities.com/registration. WallStEquities.com draws investor's attention to the Biotech industry, which is engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. The majority of a biotech company's revenue is derived from either the sale or licensing of drugs and diagnostic tools. Under observation are these four equities: Ardelyx Inc. (NASDAQ: ARDX), Array BioPharma Inc. (NASDAQ: ARRY), Audentes Therapeutics Inc. (NASDAQ: BOLD), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Monday, shares in Fremont, California headquartered Ardelyx Inc. plummeted 7.23%, ending the day at $3.85. The stock recorded a trading volume of 709,770 shares, which was above its three months average volume of 672,770 shares. The Company's shares have advanced 1.32% in the last month. The stock is trading below its 50-day moving average by 17.08%. Moreover, shares of Ardelyx, which develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the US and Asia/Pacific, have a Relative Strength Index (RSI) of 39.50. Get the full research report on ARDX for free by clicking below at:
Shares in Boulder, Colorado headquartered Array BioPharma Inc. ended the day 2.43% lower at $18.90. A total volume of 2.97 million shares was traded, which was above their three months average volume of 2.63 million shares. In the last month and the previous three months, the stock has gained 20.84% and 9.31%, respectively. Additionally, the Company's shares have advanced 108.38% over the past year. The stock is trading above its 50-day and 200-day moving averages by 19.19% and 34.35%, respectively. Furthermore, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 62.74.
On June 04th, 2018 at the American Society of Clinical Oncology annual meeting in Chicago, Illinois, Array BioPharma announced updated results from the Phase-3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as a monotherapy. Today's complimentary research report on ARRY is accessible at:
At the close of trading on Monday, shares in San Francisco, California headquartered Audentes Therapeutics Inc. finished 1.37% lower at $41.02 with a total trading volume of 393,500 shares. The stock has advanced 9.74% in the last month, 37.05% over the previous three months, and 120.30% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 8.47% and 27.85%, respectively. Additionally, shares of Audentes Therapeutics, which focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects, have an RSI of 58.35.
On June 05th, 2018, Audentes Therapeutics announced that the European Medicines Agency has granted Priority Medicines (PRIME) designation to AT132 for the treatment of X-Linked Myotubular Myopathy. The PRIME designation is intended to enhance interaction and early dialogue with developers of promising therapies to optimize development plans and speed evaluation so that these medicines may reach patients as early as possible. Register now for your free research document on BOLD at:
Victoria, Canada headquartered Aurinia Pharmaceuticals Inc.'s shares recorded a trading volume of 356,296 shares at the end of yesterday's session. The stock closed the day 1.40% lower at $5.65. The Company's shares have advanced 5.02% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 0.28% and 1.52%, respectively. Additionally, shares of Aurinia Pharma, which engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the US, China, and Switzerland, have an RSI of 46.92.
On June 22nd, 2018, Aurinia Pharma announced that the eight incumbent directors of the Company were elected at its annual general meeting held on June 21st, 2018. They are Richard Glickman, Lorin J. Randall, Benjamin Rovinski, David Jayne, Hyuek Joon Lee, George Milne, Joseph Hagan, and Michael Hayden. All other matters voted on at the meeting (including confirming the number of directors at eight and approving the appointment of PricewaterhouseCoopers LLP as auditors) were also approved. Click on the link below and see our free report AUPH at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities